Houston, Texas – 
“Our first priority is to continue to solidify the foundation of our existing digital products and services such as our Cannabis World Journals, eBooks, educational videos, sleep center and clinical studies,” said Henry Levinski, CHNC´s Treasurer. “We have set challenging goals in all of these areas and are determined to reach or exceed them; for example, we will continue to gain our proper share of the market by featuring our products in new languages such as Mandarin, French, German and Hindi.”
The company will continue to invest in its internal staff of associates, which has grown from approximately 20 to over 60 within the past year. “We are very proud of the team we have built, and we intend to continue to add value through our association of professionals all striving for our common goal of stability and growth,” said Anne Graham, CHNC’s Corporate Attorney and VP of Operations. “With this additional funding we have set a goal of building our staff to 250 by the third quarter of 2022.”
Furthermore, we will also use part of this funding to start research on the medical benefits of cannabis and the implication of cannabinoids on body homeostasis with a 18-months clinical trial on healthy individuals and patients with pathologies associated with endocannabinoid system disorders; this research aims to provide the scientific data required to establish cannabis as a safe and effective alternative in various diseases.
More importantly, we will move to establish a manufacturing facility for a number of medical, nutraceutical, and vitamin supplement products utilizing therapeutic derivatives of cannabis to assist patients suffering from diseases such as cancer, multiple sclerosis, epilepsy and many more. We are committed to working within U.S. and international laws and will only develop and distribute our products and services accordingly.
Certainly, one of the characteristics of CHNC is innovation and we are convinced that investment focused on these areas will allow us to grow and continue to yield the investment-returns (ROI) experienced so far by our investors and much more. To learn more visit: https://www.chnc-hdh.com/
Safe Harbor Statement
The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words “may,” “will,” “should,” “plans,” “explores,” “expects,” “anticipates,” “continue,” “estimate,” “projects,” “intends,” and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company’s control.
For more information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish